Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 7689923)

  • 1. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
    Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
    Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
    Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
    Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mucin 1 antigens in the serum and bronchial lavage fluid of patients with lung cancer.
    Willsher PC; Xing PX; Clarke CP; Ho DW; McKenzie IF
    Cancer; 1993 Nov; 72(10):2936-42. PubMed ID: 8221560
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucin-like carcinoma-associated antigen serum levels in patients with adenocarcinomas originating from ovary, breast and colon.
    Bon GG; Verheijen RH; Zuetenhorst JM; van Kamp GJ; Verstraeten AA; Kenemans P
    Gynecol Obstet Invest; 1996; 42(1):58-62. PubMed ID: 8840180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carcinoma-associated mucin serum markers CA M26 and CA M29: efficacy in detecting and monitoring patients with cancer of the breast, colon, ovary, endometrium and cervix.
    Yedema KA; Kenemans P; Wobbes T; van Kamp GJ; de Bruijn HW; Thomas CM; Massuger LF; Schijf CP; Bon GG; Vermorken JB
    Int J Cancer; 1991 Jan; 47(2):170-9. PubMed ID: 1988362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carcinoembryonic antigen: clinical and historical aspects.
    Martin EW; Kibbey WE; DiVecchia L; Anderson G; Catalano P; Minton JP
    Cancer; 1976 Jan; 37(1):62-81. PubMed ID: 1247968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease.
    Devine PL; Walsh MD; McGuckin MA; Quin RJ; Hohn BG; Clague A; Samaratunga H
    Int J Biol Markers; 1995; 10(4):221-5. PubMed ID: 8750649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of MSA as a serum marker in breast cancer: a comparison with CEA.
    Stacker SA; Sacks NP; Golder J; Tjandra JJ; Thompson CH; Smithyman A; McKenzie IF
    Br J Cancer; 1988 Mar; 57(3):298-303. PubMed ID: 3355770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I collagen biomarkers in the diagnosis of bone metastases in breast cancer, lung cancer, urinary bladder cancer and prostate cancer. Comparison to CEA, CA 15-3, PSA and bone scintigraphy.
    Zissimopoulos A; Stellos K; Matthaios D; Petrakis G; Parmenopoulou V; Babatsikou F; Matthaiou E; Theodosiadou E; Hountis P; Koutis C
    J BUON; 2009; 14(3):463-72. PubMed ID: 19810140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
    Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
    Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of prostate specific antigen (PSA) and carcinoembryonic antigen (CEA) in screening for prostate and recurrent colon cancers in the elderly.
    Vandenberg TA
    Clin Biochem; 1993 Dec; 26(6):429-30. PubMed ID: 7510220
    [No Abstract]   [Full Text] [Related]  

  • 12. Measurement of a monoclonal-antibody-defined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen.
    Gupta MK; Arciaga R; Bocci L; Tubbs R; Bukowski R; Deodhar SD
    Cancer; 1985 Jul; 56(2):277-83. PubMed ID: 2408729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum cytokeratin fragment 21.1 (CYFRA 21.1) as tumour marker for breast cancer: comparison with carbohydrate antigen 15.3 (CA 15.3) and carcinoembryonic antigen (CEA).
    Giovanella L; Ceriani L; Giardina G; Bardelli D; Tanzi F; Garancini S
    Clin Chem Lab Med; 2002 Mar; 40(3):298-303. PubMed ID: 12005221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of carcinoembryonic antigen and a tumor-extracted carcinoembryonic antigen-related antigen in cancer patients.
    Shively JE; Spayth V; Chang FF; Metter GE; Klein L; Presant CA; Todd CW
    Cancer Res; 1982 Jun; 42(6):2506-13. PubMed ID: 7074626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
    Meisel M; Straube W; Weise J; Burkhardt B
    Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammary serum antigen (MSA), Ca 549, CA 15-3 and CEA in breast cancer preoperative sensitivity and correlation to prognostic factors.
    Heinze T; Schürenkämper P; Minguillon C; Lichtenegger W
    Anticancer Res; 1997; 17(4B):2953-4. PubMed ID: 9329573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.
    Dolscheid-Pommerich RC; Keyver-Paik M; Hecking T; Kuhn W; Hartmann G; Stoffel-Wagner B; Holdenrieder S
    Tumour Biol; 2017 Oct; 39(10):1010428317730246. PubMed ID: 29034816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of mammary serum antigen (MSA) with beta 2-microglobulin (beta 2M) and carcinoembryonic antigen (CEA) assays in patients with breast cancer.
    Tjandra JJ; McLaughlin PJ; Russell IS; Collins JP; McKenzie IF
    Eur J Cancer Clin Oncol; 1988 Oct; 24(10):1633-40. PubMed ID: 3061824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of cancer procoagulant as an early detection tumor marker.
    Kozwich DL; Kramer LC; Mielicki WP; Fotopoulos SS; Gordon SG
    Cancer; 1994 Aug; 74(4):1367-76. PubMed ID: 8055461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new biomarker in monitoring breast cancer: CA 549.
    Beveridge RA; Chan DW; Bruzek D; Damron D; Bray KR; Gaur PK; Ettinger DS; Rock RC; Shurbaji MS; Kuhajda FP
    J Clin Oncol; 1988 Dec; 6(12):1815-21. PubMed ID: 3058875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.